BACKGROUND: Macular edema (ME) due to retinal vein occlusion can be successfully treated with intravitreal bevacizumab therapy. There is no common recommendation concerning time intervals and criteria for reinjection. METHOD: Sixty-three patients (follow-up 30+/-18 weeks) received intravitreal injections of 2.5 mg bevacizumab. Reinjection was performed only if optical coherence tomography (OCT) showed persistent or recurrent ME. Check-ups were performed every 6-8 weeks. RESULTS: There was complete resolution of macular edema in 31 patients after the first injection (improvement in visual acuity 3.7+/-3.7 lines); 65.2% of these patients developed recurrence of ME within 13.3+/-4.4 weeks, which completely resolved again after a second injection. Visual acuity gained the same level as after the first injection. Another relapse of ME in this group occurred in 69% of patients after another 13.4+/-5.4 weeks. Patients with persistent ME after the first injection (n=32) received a second injection, initially leading to resolution of ME in 33.3%, but all of these patients had a relapse within 13.9+/-4.1 weeks. CONCLUSION: OCT-guided reinjection leads to anatomic and functional stabilization or improvement even if transient recurrence of ME occurs.
BACKGROUND:Macular edema (ME) due to retinal vein occlusion can be successfully treated with intravitreal bevacizumab therapy. There is no common recommendation concerning time intervals and criteria for reinjection. METHOD: Sixty-three patients (follow-up 30+/-18 weeks) received intravitreal injections of 2.5 mg bevacizumab. Reinjection was performed only if optical coherence tomography (OCT) showed persistent or recurrent ME. Check-ups were performed every 6-8 weeks. RESULTS: There was complete resolution of macular edema in 31 patients after the first injection (improvement in visual acuity 3.7+/-3.7 lines); 65.2% of these patients developed recurrence of ME within 13.3+/-4.4 weeks, which completely resolved again after a second injection. Visual acuity gained the same level as after the first injection. Another relapse of ME in this group occurred in 69% of patients after another 13.4+/-5.4 weeks. Patients with persistent ME after the first injection (n=32) received a second injection, initially leading to resolution of ME in 33.3%, but all of these patients had a relapse within 13.9+/-4.1 weeks. CONCLUSION: OCT-guided reinjection leads to anatomic and functional stabilization or improvement even if transient recurrence of ME occurs.
Authors: Saurabh Luthra; Raja Narayanan; L Eduardo A Marques; Marilyn Chwa; Dae W Kim; Joyce Dong; Gail M Seigel; Aneesh Neekhra; Ana L Gramajo; Donald J Brown; M Cristina Kenney; Baruch D Kuppermann Journal: Retina Date: 2006 May-Jun Impact factor: 4.256
Authors: Diana Iturralde; Richard F Spaide; Catherine B Meyerle; Jay M Klancnik; Lawrence A Yannuzzi; Yale L Fisher; John Sorenson; Jason S Slakter; K Bailey Freund; Michael Cooney; Howard F Fine Journal: Retina Date: 2006-03 Impact factor: 4.256
Authors: G B Jaissle; F Ziemssen; K Petermeier; P Szurman; M Ladewig; F Gelisken; M Völker; F G Holz; K U Bartz-Schmidt Journal: Ophthalmologe Date: 2006-06 Impact factor: 1.059
Authors: J Mordenti; R A Cuthbertson; N Ferrara; K Thomsen; L Berleau; V Licko; P C Allen; C R Valverde; Y G Meng; D T Fei; K M Fourre; A M Ryan Journal: Toxicol Pathol Date: 1999 Sep-Oct Impact factor: 1.902
Authors: Sivakami A Pai; Rohit Shetty; Priya B Vijayan; G Venkatasubramaniam; Naresh K Yadav; Bhujang K Shetty; Rajesh B Babu; Kannan M Narayana Journal: Am J Ophthalmol Date: 2007-02-15 Impact factor: 5.258
Authors: Yoko Matsumoto; K Bailey Freund; Enrico Peiretti; Michael J Cooney; Daniela C A C Ferrara; Lawrence A Yannuzzi Journal: Retina Date: 2007 Apr-May Impact factor: 4.256
Authors: Melvin D Rabena; Dante J Pieramici; Alessandro A Castellarin; Ma'an A Nasir; Robert L Avery Journal: Retina Date: 2007 Apr-May Impact factor: 4.256
Authors: Thomas Ach; Alexandra E Hoeh; Karen B Schaal; Alexander F Scheuerle; Stefan Dithmar Journal: Graefes Arch Clin Exp Ophthalmol Date: 2009-09-09 Impact factor: 3.117
Authors: Alexandra E Hoeh; Thomas Ach; Karen B Schaal; Alexander F Scheuerle; Stefan Dithmar Journal: Graefes Arch Clin Exp Ophthalmol Date: 2009-07-26 Impact factor: 3.117